There were no clinically pertinent variations when compared with 2011 apart from new details and new tips with regard to the treatment method with bisphosphonates and denosumab (see area ‘Bisphosphonates and RANKL Antibody Denosumab’). In the case of invasive breast cancer, no secondary resection continues to be proposed for https://francisz863pxr5.blogdal.com/profile